Neutralizing Power of Serum Antibodies - 2

Sponsor
Centre Hospitalier Régional d'Orléans
Study ID
NCT07085611
Status
Recruiting
Apply to this trial

Conditions

  • COVID-19
  • Monkey Pox
  • Mucosal Immunity
  • SARS-CoV-2 Viraemia
  • Serum
  • Vaccination

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sample collection (blood and optional nasal swab) — OTHER
    Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur

Study Details

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.

Key Dates

First listed
Jul 25, 2025
Start date
Aug 22, 2025
Status verified
Dec 2025
Primary completion
Aug 22, 2030
Completion
Jul 11, 2035

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Other: Participants receiving vaccines and/or monoclonal antibodies
    Participants receive standard-of-care SARS-CoV-2 and/or MPXV vaccines or monoclonal antibodies. This study does not assign the treatment but collects biosamples to assess antibody response.

Primary Outcome Measure

Serum neutralizing antibody evolution (anti-SARS-CoV-2 and anti-MPXV) over time [ Time Frame: Up to 60 months ]

Central Contacts

Find similar trials

Nationwide
COVID-19 / long COVID trialsInfectious disease trials

Related Studies